According to the report published by Allied Market Research, the Australia and New Zealand fetal bovine serum market was pegged at $20 million in 2020 and is estimated to hit $35 million by 2030, registering a CAGR of 5.2% from 2021 to 2030. The report provides an in-depth analysis of the top investment pockets, top.
Benchmark reaffirmed their buy rating on shares of Bio-Techne (NASDAQ:TECH – Free Report) in a report released on Thursday, Benzinga reports. The firm currently has a $95.00 target price on the biotechnology company’s stock. Other equities research analysts have also issued research reports about the stock. Royal Bank of Canada reduced their price objective on […]
Bio-Techne (NASDAQ:TECH – Get Free Report) had its target price hoisted by equities research analysts at Robert W. Baird from $73.00 to $81.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Robert W. Baird’s price objective would suggest a potential upside […]
Bio-Techne (NASDAQ:TECH – Get Free Report) issued its quarterly earnings data on Wednesday. The biotechnology company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $0.03, Briefing.com reports. Bio-Techne had a net margin of 19.58% and a return on equity of 14.21%. The firm had revenue of $303.43 million for the […]
Bio-Techne (NASDAQ:TECH – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at Benchmark in a research note issued on Thursday, Benzinga reports. They presently have a $95.00 price target on the biotechnology company’s stock. Benchmark’s price target points to a potential upside of 27.86% from the company’s current price. TECH has […]